Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.36% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CPIX · Sep 30, 2013
CUMBERLAND PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001087294-13-000017General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-13.07% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-47.90% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
83.26% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
84.21% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-23.20% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
22.07% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
2.69% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History61 statesSelf-history eligible
Sep 30, 20217/7 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20264/4 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.12%
- Current
- 0.36%
- Delta
- 0.24%
- Previous
- 1.72%
- Current
- -13.07%
- Delta
- -14.79%
- Previous
- -42.74%
- Current
- -47.90%
- Delta
- -5.16%
- Previous
- 86.06%
- Current
- 83.26%
- Delta
- -2.81%
- Previous
- 83.69%
- Current
- 84.21%
- Delta
- 0.52%
- Previous
- -16.11%
- Current
- -23.20%
- Delta
- -7.10%
- Previous
- 19.59%
- Current
- 22.07%
- Delta
- 2.48%
- Previous
- 2.49%
- Current
- 2.69%
- Delta
- 0.20%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CPIX Fundamental State →Has State · CUMBERLAND PHARMACEUTICALS INC →Transitioned To · CPIX Fundamental State →Transitioned To · CPIX CAPEX_INTENSITY_INCREASED →Transitioned To · CPIX CASH_GENERATION_DECREASED →Transitioned To · CPIX GROWTH_DECREASED →Transitioned To · CPIX INVENTORY_PRESSURE_DECREASED →Transitioned To · CPIX MARGIN_INCREASED →Transitioned To · CPIX PROFITABILITY_DECREASED →Transitioned To · CPIX R_AND_D_INTENSITY_INCREASED →Transitioned To · CPIX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.